Navigation Links
Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
Date:9/1/2009

The available therapies have positive effects in PAH, but they do not provide a cure, and in many patients the disease will progress. PAH remains a serious life-threatening condition (2,3). Early recognition and an understanding of the selection and timing of therapeutic options remain critical elements in the optimal management of patients with this disorder.

References

  1. Farber HW; Loscalzo J. Mechanisms of disease: pulmonary arterial hypertension. N. Eng. J. Med. 2004; 351:1655-65.
  2. Humbert M; Sitbon O; Simonneau G. Treatment of pulmonary arterial hypertension. N. Eng. J. Med. 2004;351:1425-36.
  3. Humbert M; Morrell NW; Archer SL; et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2004; 43: Suppl. 12: 13S-24S.

Actelion Ltd

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(R), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(R) through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2000 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI(R)).


'/>"/>
SOURCE Actelion Pharmaceuticals US, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
2. Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information
3. GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd.
4. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
5. Novozymes Launches Enzyme to Reduce Acrylamide in Food
6. Enova Medical Launches Exos Corporation
7. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
8. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
9. ThirdBiotech Networking Group Launches
10. BioReliance Launches Next-Generation Genotoxicity Screening Service
11. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Argentina Biomedical Sensors Market - Growth, Trends & Forecasts ... The Argentina Biomedical Sensors market is estimated at $0.17 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Middle East & Africa Biomedical Sensors ... to their offering. The ... is estimated at $0.84 billion by 2018 at a ... The near future will bring Biomedical sensors that are ...
(Date:8/31/2015)... , Aug. 31, 2015  RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... announced that the 30-day review period following the ... for ocular indications with the U.S. Food and ... is now active. Logo -  ...
(Date:8/31/2015)... Aug. 31, 2015 FLX Bio, Inc., a ... novel cancer immunotherapies, announced today that it has appointed ... Officer and William Ho , M.D., Ph.D., as ... experienced management team led by veterans of Flexus Biosciences, ... Chief Scientific Officer; Jay Powers , Ph.D., Vice ...
Breaking Biology Technology:Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4
... Rhythm announced today the results of a Phase 1b ... for the treatment of diabetic gastroparesis. The trial demonstrated ... diabetic gastroparesis. The findings were presented at the Digestive ... The Phase 1b clinical trial was a randomized, double-blind, ...
... To become better healers, tissue engineering need a timely and ... already are or can become the tissue they need to ... that the stiffness, viscosity, and other mechanical properties of adult ... predict whether they will turn into bone, cartilage, or fat. ...
... New York, May 21, 2012 Elsevier,s Computers & ... on 3D Object Retrieval which will incorporate the Collage Authoring ... place winner of the 2011 Executable Paper Grand Challenge. The ... Eurographics 2012 on May 13, during the 3DOR Workshop. ...
Cached Biology Technology:Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis 2Physical properties predict stem cell outcome 2Physical properties predict stem cell outcome 3
(Date:8/5/2015)... According to a new market research report, ... (BFSI, Airport, IT & Telecom, Utilities, Education, Defense & ... published by MarketsandMarkets, defines and segments the Physical Identity ... global PIAM Market is estimated to grow from $272.2 ... a CAGR of 14.9 % from 2014 to 2019. ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Research expresses its congratulations to and appreciation of ... 2010 Leadership in Personalized Medicine Award from the Personalized ... distinguished member of the AACR for more than 20 ... the Harvard Personalized Medicine Conference on Nov. 17. According ...
... burn fossil fuels remain the main source of electricity ... to remove sulfur compounds from their flue gases, which ... researchers in India have devised a way to convert ... value-added products. They describe details in the International ...
... of a fruit fly embryo, which was taken by ... beaten-off stiff competition from hundreds of entries to win ... biodiversity. Samantha Warrington, a postgraduate student from the ... in the ,close-up category, at the Society of Biology,s ...
Cached Biology News:AACR congratulates William S. Dalton on 2010 Leadership in Personalized Medicine Award 2Snap of fruit fly embryo wins scientific photo competition 2
... detector is an optical unit that can ... or Dyad Disciple gradient-capable thermal cycler (purchased ... photonics shuttle that contains four LEDs for ... nm, 620-650 nm) and two filtered photodiodes ...
... sensitive laser confocal systems designed for rapid ... that meet your expectations, differentiating between a ... the signal on the bottom as well ... for increased sensitivity. Results with VersArray ChipReader ...
... perform 96 assays on four slides. The ... slides with 96 (6mm x 7mm) individual ... expression, or screening analysis studies. Unlike other ... gasket, eliminating the presence of contaminating adhesives. ...
... with sequence siTrio siRNA --- a ... target gene of interestis our most popular product. ... 75% knockdown of your target gene when used ... and confirmation of optimal transfection with one of ...
Biology Products: